Page 2523 - Williams Hematology ( PDFDrive )

2494 Index Index 2495

Substance P, 1878 Syngeneic hematopoietic cell transplantation, Tamm-Horsfall mucoprotein (uromodulin),
Substrate reduction therapy (SRT), 1128, 359 1744
1130 Syntaxins, 926, 1114, 1228, 1849 TAMs (tumor-associated macrophages), 1083
Succinyl coenzyme A (CoA), 892, 893f Systemic amyloidosis, 2108 TANK-binding kinase (TBK), 298, 302f
Sugar water test, 571, 576 Systemic inflammatory response syndrome, T (Thomsen-Friedenreich) antigen, 2262
Suicide genes, 416, 440, 440f 2200 TAP1/2, 1221
Sulfamethoxazole Systemic lupus erythematosus (SLE) Tapasin, 1221
hemolytic anemia and, 708 antiphospholipid syndrome and, 2238 Target cells. See Codocytes (target cells)
methemoglobinemia and, 790t antiplatelet antibodies and, 2084–2085 Targeted disruption models of
Sulfasalazine, megaloblastic anemia and, 606t aplastic anemia and, 518 hemochromatosis, 643
Sulfhemoglobin/sulfhemoglobinemia, arterial thrombosis and, 2293 Target of rapamycin complex 1 (TORC1), 192
793–794 autoimmune hemolytic anemia and, 824 TAR (thrombocytopenia and absent radii)
Sulfinpyrazone, 2075 Epstein-Barr virus infection and, 1265 syndrome, 1996, 1997f, 2061
Sulfonamides lymphocytopenia in, 1206 TAT (thrombin-antithrombin) complexes,
maternal ingestion of, effect on fetus and lymphomas and, 1574 2209
newborn, 112, 112t monocytosis in, 1097 Taxanes, 319t, 326
thrombocytopenia and, 2017 neutropenia in, 996 Taxus brevifolia, 326
toxic methemoglobinemia and, 789, 790t thrombocytopenia in, 2008–2009 TBI (total-body irradiation), 353, 359–360,
Sulindac, 2075 thrombotic microangiopathy and, 2262 1656–1657
SUMO (small ubiquitin-like modifier), 253 Systemic mastocytosis TBK (TANK-binding kinase), 298, 302f
Sunitinib with associated clonal, hematologic non- TBNP (total blood neutrophil pool), 942,
for acute myelogenous leukemia, 1404 mast-cell lineage disease, 973, 978 942t
adverse effects, 2263 classification, 973, 973t TCA (tricarboxylic acid) cycle, 192, 193f
Superoxide anion, 284t, 286 clinical features, 973–976 T-cell acute lymphoblastic leukemia (T-ALL).
Superoxide dismutase (SOD), 196, 286, 692t, course and prognosis, 978 See also Acute lymphoblastic
698 definition and history, 973 (lymphocytic) leukemia (ALL)
Superoxides, 809, 2203 differential diagnosis, 976 chromosomal abnormalities, 184t,
Suberoylanilide hydroxamic acid (SAHA), etiology and pathogenesis, 973 186–187, 186f, 222–223t
1403 indolent, 975f, 978 gene mutations, 233t
Suppressors of cytokine signaling (SOCS) laboratory features, 974, 975f, 975t, 976 laboratory features, 1511–1512, 1512t
proteins, 253, 298 therapy, 976–978 prognosis, 1520, 1521
Surface immunoglobulin, 1163 treatment, 1515–1517
Surgical procedures T T-cell antigens, 1141–1142, 1142f, 1142t
in essential thrombocythemia, 1315 T200 (CD45), 1183 T-cell-histiocyte-rich large B-cell lymphoma,
evaluation of bleeding risk during, 1990, T315I mutation, ABL1, 1457, 1457t 1636–1637
1990t Tabalumab, for myeloma, 346t, 1755 T-cell large granular lymphocytic leukemia
in hemophilia, 2120, 2123–2124 TACE (ADAM17), 1144, 1874 (T-LGLL)
hemorrhage during, 1988 Tachykinins, 1878 chromosomal abnormalities, 187
in inherited platelet disorders, 2062 TACI (transmembrane activator and calcium clinical features, 1564t, 1565–1566
in patients with factor VIII inhibition, modulator and cyclophilin ligand definition and history, 1563
2125 interactor), 1606 diagnostic criteria, 1566
platelet transfusions for, 2384 TACO (transfusion-associated circulatory differential diagnosis, 1566–1567
in polycythemia vera, 1294 overload), 2376 etiology and pathogenesis, 1563–1564
in sickle cell disease, 773 Tacrolimus gene mutations, 237t, 1498t, 1564
Surrogate λ light chains, 1168 adverse effects, 2262 histologic and immunophenotypic
SVIL, 1851 for graft-verus-host disease prevention, features, 1498t, 1565, 1565f
Sweet syndrome (neutrophilic dermatosis), 371 laboratory features, 1203, 1565–1566,
1001, 1324, 1380, 2102–2103, 2102f for IPEX syndrome, 1223 1566f
Swelling, neck, 5 for mycosis fungoides, 1685 vs. large granular lymphocytosis, 1202
SWI/SNF (switch and sucrose nonfermenting) overdose treatment, 432 therapy, course, and prognosis, 1567
remodeler, 166, 166f TAFI. See Thrombin-activatable fibrinolysis T-cell lymphoproliferation, 1265
Syk, 1054, 1880 inhibitor (TAFI) T-cell neoplasms. See also specific types
Syk, 1016 TALEN (transcription activator-like effector clinical behavior, 1493
SYK, 1696–1697 nuclease), 444 extranodal involvement, 1502
Syndecan 1 (CD138), 1141, 1712, 1714, 1737 Taliglucerase alfa, for Gaucher disease, 1127 immature, 1498t
Syndecan-4, 2202 Talin, 1832t, 1837, 1838f, 1884 leukemias, 1498t, 1571, 1573

Kaushansky_index_p2393-2506.indd 2494 9/21/15 3:22 PM